secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000886163-25-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q2 royalties up 57% to $36.4M; raises FY2025 guidance to $200-225M revenue and $6.70-7.00 adj. EPS
--------------------------------------------------------------------------------

- Q2 revenue $47.6M (+15% YoY); royalties $36.4M (+57%) driven by Qarziba and Filspari.
- GAAP net income $4.8M ($0.24 diluted) vs loss $51.9M in Q2 2024; core adj. EPS $1.60 vs $1.40.
- FY2025 guidance raised: revenue $200-225M (prev $180-200M), adj. EPS $6.70-7.00 (prev $6.00-6.25).
- Pelthos merger closed; Zelsuvmi launched July 10; Ligand earned $5M milestone and 13% royalty.
- Merck acquiring Verona for ~$10B; Ligand holds 3% royalty on Ohtuvayre (COPD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/0000886163-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/lgnd-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer